Adaptive Biotechnologies (FRA:1HM) Debt-to-Equity : 0.35 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Debt-to-Equity?

Adaptive Biotechnologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €8.8 Mil. Adaptive Biotechnologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €79.9 Mil. Adaptive Biotechnologies's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €252.9 Mil. Adaptive Biotechnologies's debt to equity for the quarter that ended in Mar. 2024 was 0.35.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Adaptive Biotechnologies's Debt-to-Equity or its related term are showing as below:

FRA:1HM' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.19 Max: 0.35
Current: 0.35

During the past 7 years, the highest Debt-to-Equity Ratio of Adaptive Biotechnologies was 0.35. The lowest was 0.04. And the median was 0.19.

FRA:1HM's Debt-to-Equity is ranked worse than
67.2% of 1061 companies
in the Biotechnology industry
Industry Median: 0.14 vs FRA:1HM: 0.35

Adaptive Biotechnologies Debt-to-Equity Historical Data

The historical data trend for Adaptive Biotechnologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Debt-to-Equity Chart

Adaptive Biotechnologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.06

0.15

0.19

0.23

0.32

Adaptive Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.25	0.26	0.28	0.32	0.35

Competitive Comparison of Adaptive Biotechnologies's Debt-to-Equity

For the Biotechnology subindustry, Adaptive Biotechnologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptive Biotechnologies's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Debt-to-Equity falls into.

Adaptive Biotechnologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Adaptive Biotechnologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8.605	+	81.969)	/	282.802
	=	0.32

Adaptive Biotechnologies's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8.826	+	79.948)	/	252.92
	=	0.35

Adaptive Biotechnologies (FRA:1HM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Adaptive Biotechnologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptive Biotechnologies (FRA:1HM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ADPT:USA

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Adaptive Biotechnologies (FRA:1HM) Headlines

No Headlines